Joshua Aiello, Principal Accounting Officer of Orchestra BioMed Holdings, Inc., filed a Statement of Changes in Beneficial Ownership on August 28, 2026, reporting a disposition of common shares on August 26, 2026 in connection with restricted stock unit vesting.

Key Highlights

  • Reporting person: Joshua Aiello, identified as Principal Accounting Officer of Orchestra BioMed Holdings, Inc.
  • Transaction type: 203 shares of Common Stock, par value $0.0001 per share, were disposed of under transaction code "F" at a price of $5.26 per share on August 26, 2026.
  • Purpose of disposition: According to the filing, the shares represent withholding by the issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units (RSUs); no shares were sold in the open market.
  • Post-transaction ownership: Following the reported transaction, Aiello directly beneficially owned 18,441 shares of common stock.
  • Filing date: The statement was filed on August 28, 2026, and signed by Andrew Taylor as Attorney-in-Fact.

Share Withholding Details for Orchestra BioMed Holdings Officer

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), a medical device and biotherapeutics company headquartered in New Hope, Pennsylvania, was the issuer named in this beneficial ownership statement. The filing covers a single transaction in Table I involving non-derivative securities, with no derivative securities reported in Table II.

According to the filing, 203 shares of Common Stock, par value $0.0001 per share, were withheld by the issuer on August 26, 2026, at a price of $5.26 per share. The filing states that this represents "the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units" and that "no shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations." The transaction code recorded is "F," consistent with a tax withholding disposition rather than an open-market sale.

Following the reported transaction, Aiello's direct beneficial ownership in Orchestra BioMed Holdings common stock stood at 18,441 shares, according to the filing. The statement was filed individually by one reporting person and was not designated as an amendment to a prior filing. Andrew Taylor signed the document as Attorney-in-Fact on behalf of Aiello on August 28, 2026.

What Was Disclosed

The filing disclosed a single tax-related share withholding transaction by Orchestra BioMed Holdings' Principal Accounting Officer, Joshua Aiello, involving 203 shares of common stock at $5.26 per share on August 26, 2026, leaving him with 18,441 shares of direct beneficial ownership.